Real-world effectiveness of osteoporosis treatment in the oldest old

• Published in: Osteoporosis international Vol. 31; no. 8; pp. 1525 - 1533
• Main Authors: Ström, O., Lauppe, R., Ljunggren, Ö., Spångéus, A., Ortsäter, G., O’Kelly, J., Åkesson, K.
• Format: Journal Article
• Language: English
• Published: London Springer London 01-08-2020; Springer Nature B.V
• Subjects: Aged, 80 and over; Allmänmedicin; Bisphosphonates; Bone Density; Bone Density Conservation Agents - therapeutic use; Bone mineral density; Calcium; Clinical Medicine; Clinical trials; Dual energy X-ray absorptiometry; Elderly; Endocrinology; Family Medicine; Female; Fractures; Fractures, Bone - epidemiology; Hip; Humans; Klinisk medicin; Medical and Health Sciences; Medicin och hälsovetenskap; Medicine; Medicine & Public Health; Oldest old people; Original; Original Article; Orthopedics; Ortopedi; Osteoporosis; Osteoporosis - drug therapy; Patients; Register; Retrospective; Rheumatology; Sweden - epidemiology; Treatment Outcome; Vertebrae; Vitamin D; Women; Sweden; Women; Bone mineral density; Register; Bisphosphonates; Elderly; Retrospective
• ISSN: 0937-941X; 1433-2965; 1433-2965
• DOI: 10.1007/s00198-020-05380-6

Summary
We studied effectiveness of osteoporosis treatment in women older than 80 years, who often are not included in clinical trials. Treatments were as effective on bone density and fractures as in younger women.
Introduction
To study real-world effectiveness of osteoporosis treatment on BMD and fractures in the oldest old women (≥ 80 years) compared with women (60–79 years) in the clinical setting using Swedish health register data.
Methods
National registers and data from DXA machines were used to study effectiveness of all available osteoporosis treatments in women 60–79 and ≥ 80 years using three approaches: (1) Total Hip BMD change up to 8 years after treatment start; (2) fracture incidence where patients served as their own controls, comparing the first 3 months after treatment start with the subsequent 12 months; and (3) comparison of fracture incidence post-fracture in women ≥ 80 years treated with osteoporosis treatment or calcium/vitamin D.
Results
Analysis 1: Total Hip BMD increased by up to 6.7% and 7.7% in women 60–79 and ≥ 80 years old, respectively. The mean increase in BMD was 1.1%-units per year in both age groups. Analysis 2: Relative to the 3-month baseline, fracture incidence decreased during the subsequent 12 months of treatment. Incidence rate ratios were estimated at 0.65, 0.74, 0.29, and 0.81 for any, hip, vertebral, and non-hip-non-vertebral fracture, respectively. Analysis 3: A 24-month incidence of any fracture in women ≥ 80 years given post-fracture osteoporosis treatment was lower (HR = 0.78) than in women given calcium/vitamin D, but treatment allocation was not random, with lower mortality (HR = 0.51) in patients receiving OP treatment.
Conclusions
Osteoporosis medication in women > 80 years in clinical practice likely works, and the magnitude of effect is similar to what was estimated in younger women. The choice between osteoporosis treatment and calcium/vitamin D after fracture in women ≥ 80 years is not random but appears associated with the patient’s health status and presence of vertebral fractures, rather than the known risk profile of sustaining a fracture at a high age.